<?xml version="1.0" encoding="UTF-8"?>
<p>Dimethyl sulfoxide (DMSO), α-terpinene, myrcene, (−)-limonene, (+)-limonene, and 
 <italic>p</italic>-cymene were purchased from Acros Organics (Fair Lawn, NJ, USA). Carvacrol and thymol were purchased from Tokyo Chemical Industry Co. (Tokyo, Japan). Camphene, γ-terpinene, (−)-linalool, sabinene, and α-terpineol were from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Terpinolene and α-pinene (mixture of isomers) were from Santa Cruz Biotech (Dallas, TX, USA), (1
 <italic>S</italic>)-(−)-β-pinene and terpinen-4-ol were from Alfa-Aesar (Ward Hill, MA, USA), and 
 <italic>n</italic>-hexane was purchased from Merck (Darmstadt, Germany). TRPA1 antagonist HC-030031 was from Tocris Bioscience (Ellisville, MS, USA). Stock concentrations of monoterpenes were prepared in DMSO. Hanks’ balanced salts (HBSS) were purchased from Sigma-Aldrich (H1387; St. Louis, MO, USA). The calcium indicator dye Fura-2 acetoxy methylester (Fura 2-AM) was purchased from AAT-Bioquest (Sunnyvale, CA, USA). Working concentrations of treatments were prepared in HBSS.
</p>
